Euro
USD
British Pound
NULL
Product Description
Brentuximab Vedotin (TNFRSF8/CD30 ) Antibody, Monoclonal | 10-337 | ProSci
Host: N/A
Reactivity: N/A
Homology: N/A
Immunogen: Chimeric / TNFRSF8/CD30 [Homo sapiens]
Research Area: Drug Analogues
Tested Application: N/A
Application: N/A
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: >95%
Clonality: Monoclonal
Clone: N/A
Isotype: IgG1-kappa
Conjugate: Unconjugated
Physical State: N/A
Buffer: PBS buffer pH7.5
Concentration: N/A
Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.
Alternate Name: SGN-35, cAC10-Val-Cit-MMAE
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Brentuximab vedotin是靶向CD30的新型抗体偶联药物（ADC），MMAE（一种微管抑制剂）通过共价键与抗体相连。非临床数据表明，Brentuximab vedotin的抗肿瘤活性是通过ADC与CD30表达细胞形成的复合物内化及蛋白水解切割，释放MMAE。随后MMAE与微管蛋白结合，破坏细胞内的微管网络，诱导细胞周期停滞和细胞凋亡。
